Jesse's Journey Foundation

Defeat Duchenne. Change Lives.

News & Resources

May is Defeat Duchenne Month

May 1 marks the beginning of Defeat Duchenne Month! During the month of May, families, businesses, and schools across Canada raise funds and awareness for Duchenne muscular dystrophy research. It’s easy to take part in Defeat Duchenne Month! Here are a few fundraising ideas: Gather a group of friends, family members, or co-workers and register for […]


Portrait of Duchenne: John and Jesse

John Davidson recently sat down with La Force DMD, a Duchenne muscular dystrophy advocacy organization based out of Quebec, as part of their “Portrait of Duchenne” series. They are releasing a series of videos featuring stories with those who face Duchenne muscular dystrophy every day – patients, parents, family members, and researchers. In his interview, […]


Capricor Initiates HOPE-2 Clinical Trial of Duchenne Drug

This morning, Capricor Therapeutics, Inc. announced that the HOPE-2 clinical trial has been initiated at UC Davis Medical Center in Sacramento, CA. The trial will evaluate the efficacy and safety of Capricor’s novel cellular treatment, CAP-1002, in boys and young men with Duchenne muscular dystrophy (DMD), a devastating and life-threatening genetic disorder with few therapeutic […]


Ezutromid Shows Potential in DMD

Phase II study indicates modulating utrophin may reduce muscle inflammation LOS ANGELES — The investigative utrophin modulator ezutromid showed promise in treating Duchenne muscular dystrophy, according to a interim analysis of an open-label, phase II clinical trial. Ezutromid appeared to have significantly deceased inflammation in the calf muscle of Duchenne patients after 24 weeks, reported […]


Edasalonexent Could Reduce Functional Decline in Boys with DMD, MoveDMD Phase 2 Results Suggest

Results of the Phase 2 MoveDMD trial showed that Catabasis Pharmaceuticals’ candidate drug edasalonexent (CAT-1004) can reduce the rate of functional decline in boys ages 4–7 with Duchenne muscular dystrophy (DMD). The recent findings will be subject of a presentation titled, “MoveDMD: Phase 2 Trial of Edasalonexent, an NF-kB Inhibitor, in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy,” […]


A Note from John Davidson, April 26

Editor’s Note: Just before I write my 20-years-ago today piece, I want to thank all those who attended the anniversary gala in London on April 10th. We premiered a new documentary at that time and we had greetings from Ottawa. I am providing the links for these pieces in the hope that you will enjoy [...]

#AAN2018 – Early Data Supports Golodirsen in DMD Patients Amenable to Exon 53 Skipping

A potential next-generation therapy, golodirsen (SRP-4053) facilitates and increases dystrophin production in Duchenne muscular dystrophy (DMD) patients, an interim analysis of a Phase 1/2 trial being presented at the 2018 American Academy of Neurology (AAN) Annual Meeting in Los Angeles reports. These findings, in  “Golodirsen Induces Exon Skipping Leading to Sarcolemmal Dystrophin Expression in Duchenne Muscular Dystrophy Patients With Mutations […]


Summit Presents New 24-Week Analyses from PhaseOut DMD at the 2018 American Academy of Neurology Annual Meeting

OXFORD, United Kingdom and CAMBRIDGE, Mass., April 20, 2018 (GLOBE NEWSWIRE) — Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces the presentation of new 24-week interim analyses from PhaseOut DMD, a Phase 2 open-label, multi-centre clinical trial of the utrophin modulator ezutromid in Duchenne muscular dystrophy (‘DMD’), at the 70th American Academy of Neurology Annual Meeting (‘AAN’). These new […]


#AAN2018 – Clinical Trials Re-Analysis Shows Emflaza Potential to Preserve Motor Function in Boys with DMD

Treatment with Emflaza (deflazacort) is better at preserving motor function in patients with Duchenne muscular dystrophy (DMD) than standard of care corticosteroid treatments, according to a re-analysis of data from two clinical trials. The new findings follow a reassessment of pooled data obtained in the placebo group of the Study 007 Phase 2b (NCT00592553) and ACT DMD Phase 3 (NCT01826487) […]


A Note from John Davidson, April 19

20-years-ago today it was constant rain and bitter cold as I moved along the Trans-Canada Highway, finishing my day in Glovertown, Newfoundland. It’s been a soggy week. My soaking wet wind suit has been flapping tight against my body like a flag snapping in a stiff wind. The rain is always there and eventually it [...]

Disclaimer: Jesse's Journey provides the above information as a potential resource for our visitors. We do not verify the accuracy or truth of third party information and cannot be responsible for the quality of the information or services provided by other organizations and mentioned on our website, nor do we endorse any service, product, treatment or therapy.